Clinical Watch: October 2018

October 29, 2018

In this issue of Clinical Watch, we discuss filgrastim and its biosimilars. We suggest criteria for the first oral treatment of Fabry disease and review a study evaluating the timing of opioid use disorder treatment in adolescents and young adults. Lastly, we review the utilization of ADHD stimulants across age groups.

For more information about our solutions, please visit conduent.com/pharmacysolutions.

Previous Flipbook
Clinical Watch: November 2018
Clinical Watch: November 2018

In October 2018, the FDA approved an expanded indication of the HPV vaccine Gardasil 9® to include females ...

Next Flipbook
Clinical Watch: October 2018
Clinical Watch: October 2018